Nanotechnological Toolkits for Multi-Modal Disease Diagnostics and Treatment Monitoring (NAMDIATREAM)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2010
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Oncology
  • Location: Europe

Abstract

Mission

Nanotechnological Toolkits for Multi-Modal Disease Diagnostics and Treatment Monitoring (NAMDIATREAM) will develop a cutting-edge, nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory, and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific “lab-on-a-bead,”“lab-on-a-chip,” and “lab-on-a-wire” nano-devices utilizing photoluminescent, plasmonic, magnetic, and nonlinear optical properties of nanomaterials. This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturization, and reproducibility. The ETP in Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. More than 3.2 million new cases and 1.7 million cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification.

NAMDIATREAM will deliver the following:

Financing

NAMDIATREAM is co-funded by the European Community under the Seventh Framework Programme.

Impact/Accomplishment

NAMDIATREAM has successfully developed a nanotechnology-based toolkit to enable early detection and imaging of molecular biomarkers of the most common cancer types (e.g., breast, lung, and prostate) and of cancer metastases, as well as permitting the identification of cells indicative of early-stage disease onset. The project is built on the innovative technology concepts of super-sensitive “lab-on-a-bead,” “lab-on-a-chip,” and “lab-on-a-wire” nano-devices.

NAMDIATREAM has delivered photoluminescent nanoparticle-based reagents and diagnostic chips for high-throughput early diagnosis of cancer and treatment. They allow for identification of true “molecular signatures” of specific biomarkers and cancer cells within diagnostic material. The validation of these nano-tools has been carried out in compliance with the OECD regulatory policies in nano-materials.

Points of Contact

Administrative Contact
Deirdre Savage
phone: +35318961942
fax: +35317071633

Sponsors & Partners

Advanced Accelerator Applications

Austrian Institute of Technology

Becton Dickinson and Company Biosciences Europe

Cellix Limited

Ecole Polytechnique Federale de Lausanne

Edelsteine/Edelmetalle GmbH

INNOVA S.p.A.

INSERM

Institut National des Sciences Appliquees de Toulouse

Max-Planck

NanoSight Limited

Nikon Instruments France

Philipps Universitat Marburg

Progenika Biopharma S.A.

Radisens Diagnostics Limited

Selective Antibodies Limited

Technical University BraunSchweig

Trinity College Dublin

Universite de Geneve

Universite de Savoie

University College Dublin

University of Reims Champagne-Ardenne


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.